Artefactum - revista de estudos interdisciplinares
Cure8 research brief
Why This Matters
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and surgical care can change long-term disease course.
It also highlights factors (barrier failure, dysbiosis, immune pathways) that underlie symptoms and treatment responses.
Who Should Pay Attention
Adult patients with ulcerative colitis or Crohn’s disease, clinicians managing IBD, surgeons, and IBD researchers interested in treatment strategies, microbiome and immune mechanisms, and postoperative management.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article is an integrative review (abstract-level) comparing medical and surgical management of ulcerative colitis and Crohn’s disease, and summarizing inflammatory mechanisms, microbiome changes, treatment outcomes, and surgical results including IPAA and recurrence after resections.
It synthesizes published data (2020–2025) on mucosal healing, biologics, small molecules, anti-drug antibodies, and surgical outcomes; the review supports a Treat-to-Target approach and emphasizes multidisciplinary care and postoperative biologic therapy in Crohn’s to lower recurrence.
Key quantitative points (e.g., percentages, relative risks) are reported in the abstract; this brief is grounded in the article abstract and not a full independent appraisal of primary studies.
Keep In Mind
This entry summarizes findings reported in the article abstract of an integrative review; it does not represent new clinical trial results. Reported statistics are those the authors extracted from reviewed studies (2020–2025). Individual treatment decisions should be based on clinical consultation and guideline recommendations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationArtefactum - revista de estudos interdisciplinares
PublisherEditoriales Iberoamericanos
AuthorsHenrique Capuruço Costa Guimarães, Matheus Sandoli Matozinhos Lisboa, Marina Camarão Oliveira +5 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedAug 6, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Do You Need to Treat Asymptomatic Crohn’s Disease?
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
Autologous Stem Cell Transplant for Crohn's Disease
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
A Case of Elderly-Onset Ulcerative Colitis with Large-Vessel Giant Cell Arteritis Treated Successfully with Tofocitinib.
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.